SARS-CoV-2-induced dysregulation in ADAR editing patterns persists post viral clearance in individuals with mild COVID-19.

Publication date: Apr 15, 2026

Innate immune response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection activates multiple interferon stimulated genes (ISGs), including ADAR1 p150 isoform, which edits adenosine (A) residues within double stranded RNAs in both the virus and the host. In addition to its immune role, ADAR editing also serves as a mechanism of dynamic regulation of transcriptome and proteome diversity. While evidence points to changes in ADAR editing during infection, we do not know whether editing targets change over the course of the infection. Here, we explored temporal changes in ADAR expression and editing patterns, across three distinct stages of SARS-CoV-2 infection. Furthermore, we examined whether infection-triggered dysregulation in ADAR editing persists or returns to pre-infection states post-viral clearance using publicly available whole blood RNA sequencing samples from forty-five, age-matched individuals. The individuals selected had no documented comorbidities, developed mild COVID-19, and were sampled across three distinct stages of SARS-CoV-2 infection: pre-, mid-, and post-infection. Our results demonstrate dynamic changes in ADAR expression and editing across the three stages. We further identified editing sites that were edited only in one of the three stages of infection within genes involved in immune response pathways, specifically, within neutrophil degranulation pathway genes. Our results demonstrate a consistent trend of elevated ADAR expression and reduced overall ADAR editing within each individual mid-infection. Subsequently, post-infection, though ADAR expression returns to pre-infection levels, ADAR editing remains dysregulated in some individuals. Given that dysregulated ADAR editing could be a mechanistic link between viral infections and sequalae, it is possible that persistent dysregulation of ADAR editing in a subset of recovered individuals contributes to the heterogeneity in disease outcomes seen in individuals post-SARS-CoV-2 infection.

Open Access PDF

Concepts Keywords
Blood ADAR editing
Coronavirus ADAR protein, human
Covid Adenosine Deaminase
Mild Adenosine Deaminase
Transcriptome Adult
CHARM trial
COVID-19
Female
Humans
Immunity, Innate
Male
Middle Aged
RNA Editing
RNA editing
RNA-Binding Proteins
RNA-Binding Proteins
SARS-CoV-2
SARS-CoV-2
Transcriptome
transcriptome

Semantics

Type Source Name
disease MESH COVID-19
disease MESH Severe Acute Respiratory Syndrome
disease MESH infection
drug DRUGBANK Adenosine
pathway REACTOME SARS-CoV-2 Infection
pathway REACTOME Neutrophil degranulation
disease MESH viral infections
pathway REACTOME Reproduction
disease MESH sore throat
disease MESH fever
disease MESH dyspnea
disease MESH fatigue
disease MESH myalgia
disease MESH cough
disease MESH pneumonia
disease MESH acute respiratory distress syndrome
disease MESH ered
drug DRUGBANK Topiramate
disease MESH Influenza
disease MESH Rift Valley fever
disease MESH hepatitis
disease MESH Zika virus infection
disease MESH reovirus infection
disease MESH included
drug DRUGBANK Methionine
pathway REACTOME Immune System
drug DRUGBANK Natural alpha interferon
pathway REACTOME Complement cascade
drug DRUGBANK Zinc
drug DRUGBANK Trihexyphenidyl
pathway REACTOME Signal Transduction
disease MESH cancer
drug DRUGBANK Vitamin E
disease MESH death
drug DRUGBANK Nonoxynol-9
disease MESH ncRNA
pathway REACTOME Metabolism
pathway REACTOME mRNA Editing
pathway REACTOME Extracellular matrix organization
pathway REACTOME Invadopodia formation
pathway KEGG Arachidonic acid metabolism
drug DRUGBANK Aspartame
drug DRUGBANK Ademetionine
disease MESH lung diseases
pathway REACTOME HCMV Infection
pathway REACTOME Apoptosis
pathway REACTOME Translation
disease MESH inflammation
disease MESH asthma
pathway KEGG Asthma
disease MESH acute lung injury
disease MESH arthritis
disease MESH septic shock
drug DRUGBANK Coenzyme M
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH abdominal pain
disease MESH chills
disease MESH diarrhea
disease MESH headache
disease MESH nausea
disease MESH runny nose
drug DRUGBANK Guanosine
disease MESH schizophrenia
disease MESH Dis
disease MESH astrocytomas
pathway KEGG Viral replication
disease MESH multiple sclerosis
disease MESH Gan
drug DRUGBANK Pegademase bovine
drug DRUGBANK Ranitidine
disease MESH Acc
disease MESH Allergy
disease MESH glioma
pathway KEGG Glioma
pathway REACTOME Fatty acid metabolism
drug DRUGBANK Naloxone
disease MESH Park
drug DRUGBANK L-Aspartic Acid
disease MESH syndromes
disease MESH glioblastoma
disease MESH measles
pathway KEGG Measles
disease MESH encephalopathy
disease MESH long COVID
disease MESH strains
disease MESH infectious disease
pathway REACTOME Infectious disease

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *